4,5-dimethoxy-2-oximino-1-indanone | 38489-91-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4,5-dimethoxy-2-oximino-1-indanone
• 英文别名: 4,5-dimethoxy-indan-1,2-dione-2-oxime；4,5-Dimethoxy-indan-1,2-dion-2-oxim；(2E)-2-hydroxyimino-4,5-dimethoxy-3H-inden-1-one
• CAS: 38489-91-7
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: FJSOPRNCFOYSOY-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,5-dimethoxy-2-oximino-1-indanone 在 palladium on activated charcoal 硫酸 、 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 2-amino-4,5-dimethoxyindan
  参考文献：
  名称：

  Conformationally restricted congeners of dopamine derived from 2-aminoindan

  摘要：

  Two series of N-substituted 2-aminoindan systems have been prepared: 4,5-dihydroxy-2-aminoindan (1) has a hydroxylation pattern analogous to the alpha conformer of dopamine, and 5,6-dihydroxy-2-aminoindan (2) has a hydroxylation pattern of the beta conformer of dopamine. All members of both series demonstrated only extremely weak binding to calf caudate homogenate. Certain N-alkylated 4,5-dihydroxyindans were violent emetics in the dog and were potent in blockade of the effect of stimulation of the cardioaccelerator nerve of the cat. In contrast, the 5,6-dihydroxy series displayed low or no activity/potency in these assays. Conformational analysis of the 2-aminoindan system is described and discussed.

  DOI：

  10.1021/jm00354a010
• 作为产物：
  描述：

  4,5-二甲氧基-1-茚酮 在 盐酸 、 亚硝酸丁酯 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以80%的产率得到4,5-dimethoxy-2-oximino-1-indanone
  参考文献：
  名称：

  Conformationally restricted congeners of dopamine derived from 2-aminoindan

  摘要：

  Two series of N-substituted 2-aminoindan systems have been prepared: 4,5-dihydroxy-2-aminoindan (1) has a hydroxylation pattern analogous to the alpha conformer of dopamine, and 5,6-dihydroxy-2-aminoindan (2) has a hydroxylation pattern of the beta conformer of dopamine. All members of both series demonstrated only extremely weak binding to calf caudate homogenate. Certain N-alkylated 4,5-dihydroxyindans were violent emetics in the dog and were potent in blockade of the effect of stimulation of the cardioaccelerator nerve of the cat. In contrast, the 5,6-dihydroxy series displayed low or no activity/potency in these assays. Conformational analysis of the 2-aminoindan system is described and discussed.

  DOI：

  10.1021/jm00354a010

文献信息

• Isoquinoline aminopyrazole derivatives
  申请人：Chen Li

  公开号：US20070179151A1

  公开（公告）日：2007-08-02

  The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

  本发明涉及式I的化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋体，以及制备这些化合物，含有它们的制药组合物和其制造，以及在控制或预防癌症等疾病中使用这些化合物的用途。
• Perkin; Robinson, Journal of the Chemical Society, 1914, vol. 105, p. 2384
  作者：Perkin、Robinson

  DOI：——

  日期：——
• Physiologically Active Indanamines. II. Compounds Substituted in the Aromatic Ring¹
  作者：R. V. Heinzelmann、H. G. Kolloff、James H. Hunter

  DOI：10.1021/ja01184a028

  日期：1948.4
• US7572809B2
  申请人：——

  公开号：US7572809B2

  公开（公告）日：2009-08-11
• [EN] ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'AMINOPYRAZOLE DE TYPE ISOQUINOLÉINE, LEUR FABRICATION ET APPLICATION EN TANT QU'AGENTS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007071348A1

  公开（公告）日：2007-06-28

  [EN] Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
  [FR] La présente invention a pour objet les composés de formule (I), leurs sels de qualité pharmaceutique, leurs formes énantiomères, leurs diastéréoisomères et leurs racémates, la synthèse des composés susmentionnés, les médicaments les contenant et leur fabrication, ainsi que l'emploi des composés susmentionnés dans le contrôle ou la prévention de maladies telles que le cancer.